Flexion Therapeutics, Inc. (FLXN) Earns Buy Rating from Northland Securities

Northland Securities reissued their buy rating on shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) in a report published on Friday. Northland Securities currently has a $40.00 price objective on the specialty pharmaceutical company’s stock.

A number of other analysts have also commented on FLXN. Zacks Investment Research lowered shares of Flexion Therapeutics from a hold rating to a sell rating in a report on Thursday, July 13th. Royal Bank Of Canada reaffirmed an outperform rating and set a $44.00 target price on shares of Flexion Therapeutics in a report on Thursday, August 10th. Needham & Company LLC reaffirmed a buy rating and set a $36.00 target price (up previously from $34.00) on shares of Flexion Therapeutics in a report on Thursday, August 10th. BMO Capital Markets reaffirmed a buy rating on shares of Flexion Therapeutics in a report on Friday, August 11th. Finally, ValuEngine raised shares of Flexion Therapeutics from a sell rating to a hold rating in a report on Friday, September 1st. One analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of Buy and an average target price of $98.33.

Shares of Flexion Therapeutics (NASDAQ:FLXN) opened at $23.99 on Friday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 12.93 and a current ratio of 12.93. Flexion Therapeutics has a fifty-two week low of $15.96 and a fifty-two week high of $32.25.

COPYRIGHT VIOLATION WARNING: “Flexion Therapeutics, Inc. (FLXN) Earns Buy Rating from Northland Securities” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://ledgergazette.com/2017/11/13/flexion-therapeutics-inc-flxn-earns-buy-rating-from-northland-securities.html.

In other news, insider Michael D. Clayman purchased 5,000 shares of Flexion Therapeutics stock in a transaction dated Wednesday, November 8th. The shares were bought at an average cost of $23.60 per share, with a total value of $118,000.00. Following the completion of the transaction, the insider now directly owns 35,395 shares in the company, valued at approximately $835,322. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Yamo Deniz purchased 1,375 shares of Flexion Therapeutics stock in a transaction dated Thursday, August 31st. The shares were purchased at an average cost of $25.40 per share, for a total transaction of $34,925.00. Following the completion of the transaction, the insider now owns 5,000 shares of the company’s stock, valued at $127,000. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 10,375 shares of company stock worth $249,575. Insiders own 15.98% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of FLXN. Fiduciary Trust Co. bought a new stake in Flexion Therapeutics in the 2nd quarter valued at $101,000. IFP Advisors Inc lifted its position in Flexion Therapeutics by 24.5% in the 2nd quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock valued at $103,000 after acquiring an additional 1,000 shares in the last quarter. Advisor Group Inc. lifted its position in Flexion Therapeutics by 205.9% in the 2nd quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock valued at $105,000 after acquiring an additional 3,500 shares in the last quarter. SG Americas Securities LLC bought a new stake in Flexion Therapeutics in the 3rd quarter valued at $135,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in Flexion Therapeutics in the 3rd quarter valued at $235,000. 69.17% of the stock is currently owned by institutional investors and hedge funds.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply